387 related articles for article (PubMed ID: 17916445)
1. TNFalpha blockade in human diseases: an overview of efficacy and safety.
Lin J; Ziring D; Desai S; Kim S; Wong M; Korin Y; Braun J; Reed E; Gjertson D; Singh RR
Clin Immunol; 2008 Jan; 126(1):13-30. PubMed ID: 17916445
[TBL] [Abstract][Full Text] [Related]
2. TNFalpha blockade in human diseases: mechanisms and future directions.
Wong M; Ziring D; Korin Y; Desai S; Kim S; Lin J; Gjertson D; Braun J; Reed E; Singh RR
Clin Immunol; 2008 Feb; 126(2):121-36. PubMed ID: 17916444
[TBL] [Abstract][Full Text] [Related]
3. TNFalpha as therapeutic target: new drugs, more applications.
Reimold AM
Curr Drug Targets Inflamm Allergy; 2002 Dec; 1(4):377-92. PubMed ID: 14561184
[TBL] [Abstract][Full Text] [Related]
4. Biological and clinical effects of anti-TNFalpha treatment.
Valesini G; Iannuccelli C; Marocchi E; Pascoli L; Scalzi V; Di Franco M
Autoimmun Rev; 2007 Nov; 7(1):35-41. PubMed ID: 17967723
[TBL] [Abstract][Full Text] [Related]
5. TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases.
Wiedmann MW; Mössner J; Baerwald C; Pierer M
Endocr Metab Immune Disord Drug Targets; 2009 Sep; 9(3):295-314. PubMed ID: 19594416
[TBL] [Abstract][Full Text] [Related]
6. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
[TBL] [Abstract][Full Text] [Related]
7. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
Nesbitt A; Fossati G; Bergin M; Stephens P; Stephens S; Foulkes R; Brown D; Robinson M; Bourne T
Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564
[TBL] [Abstract][Full Text] [Related]
9. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France.
Saint Marcoux B; De Bandt M;
Joint Bone Spine; 2006 Dec; 73(6):710-3. PubMed ID: 17127088
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results.
Doycheva D; Zierhut M; Blumenstock G; Stuebiger N; Januschowski K; Voykov B; Deuter C
Br J Ophthalmol; 2014 Apr; 98(4):523-8. PubMed ID: 24457365
[TBL] [Abstract][Full Text] [Related]
11. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
12. Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy.
Wendling D; Balblanc JC; Briançon D; Brousse A; Lohse A; Deprez P; Humbert P; Aubin F
Joint Bone Spine; 2008 May; 75(3):315-8. PubMed ID: 18329935
[TBL] [Abstract][Full Text] [Related]
13. [Anti-TNFα therapy in ankylosing spondylitis: symptom control and structural damage modification].
Andreu JL; Otón T; Sanz J
Reumatol Clin; 2011; 7(1):51-5. PubMed ID: 21794779
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
[TBL] [Abstract][Full Text] [Related]
15. [Approved indications and other possible utilizations of anti-TNFα biologic drugs].
Grassi W; Montecucco C
Reumatismo; 2005; 57(4 Suppl):30-3. PubMed ID: 16385353
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and security of tumor necrosis factor antagonists in the treatment of rheumatoid arthritis].
Pérez Pampín E; Gómez-Reino Carnota JJ
Med Clin (Barc); 2008 Feb; 130(5):179-87. PubMed ID: 18341834
[TBL] [Abstract][Full Text] [Related]
17. [Inhibitors of TNFalpha].
Brousse C
Rev Med Interne; 2003 Feb; 24(2):123-6. PubMed ID: 12650894
[TBL] [Abstract][Full Text] [Related]
18. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
19. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
Collamer AN; Battafarano DF
Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
[TBL] [Abstract][Full Text] [Related]
20. Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease.
Chang JT; Lichtenstein GR
Nat Clin Pract Gastroenterol Hepatol; 2006 Apr; 3(4):220-8. PubMed ID: 16582964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
